



#معكم_خطوة_بخطوة

Thrombosis

"The formation of unwanted clot within a blood vessel"

- Myocardial Infarction (MI) (cardiac ischemia caused by occlusion of coronary arteries by clot)
- Deep Venous Thrombosis (DVT)
- Pulmonary Embolism (PE) (occlusion by embolus in the Pulmonary circulation)
- Cerebrovascular Accident (CVA) (occlusion of blood vessels that supply the brain)

Thrombus vs Embolus

• What is the difference?

thrombus :the formation of blood clot in the blood vessels at the primary site

embolus: fragmentation and dislodgment of the thrombus to the blood stream

ممكن يروح يسكر مكان ثاني



Arterial thrombosis vs venous thrombosis

- What is the difference?
- Arterial thrombosis: platelet-rich clot
- Venous thrombosis: blood stasis/pathological activation of the coagulation cascade



Three main players:

- 1. Endothelium
- 2. Platelets
- 3. Coagulation Pathway

vasospasm \rightarrow formation of platelet-fibrin plug \rightarrow thrombus formation

اول اشـي بصير vasospasm يعني الblood vessel بصير فيه contraction بالsmooth muscles عشـان نقلل الblood loss

Resting Platelets

بالوضع الطبيعي الplatelets بكونوا inactive لانو ما في bleeding ولا tissue damage

والendothelium بكونintact

والcollagen بكون متخبيnot exposed

وحدة من الاشياء المهمة اللي بتخلي الplatelets

Resting platelets Healthy, intact endothelial cells Subendothelium Collagen fibers

بالresting state هو الPG I

Monitor the integrity of the vascular endothelium Prostacyclin PG I₂:

- Synthesized by intact endothelial cells
- Inhibits platelet aggregation (bind to receptors on the platelets)

 Prostacyclin binds to platelet membrane receptors, causing synthesis of cAMP. cAMP stabilizes inactive GP IIb/IIIa receptors and inhibits release of granules containing platelet aggregation agents or Ca²⁺. 	Inactive GP IIb/IIIa receptors Ca ²⁺ G ²⁺ ATP S ⁻ AMP Batelet Prostacyclin Nitric oxicle Endothelial cells
) من انو يطلع بالتالي بمنع الactivation of platelets	بمنع ال⁺Ca
What else can bind to the resting س الPG بالتالي بعملوا activation للplatelets	<mark>platelet?</mark> کلهم بشتغلوا عک
 Thrombin Thromboxanes Exposed collagen 	
release of granules containing platelet aggregation agents or Ca ²⁺ . activation of platelets العني التالي بمنغ التالي المنغ Ca ²⁺ من الو يطلع بالتالي بمنغ Ca ²⁺ المنغ What else can bind to the resting platelet? platelets U activation المالي بعملوا PG بالتالي بعملوا عكس ال PG بالتالي بعملوا عكس ال PG بالتالي بعملوا عكس ال Platelet Adhesion • Thrombin • Thromboxanes • Exposed collagen • Platelets adhere to exposed collagen • Platelets adhere to exposed collagen • Collagen binding results in platelet activation	
 Platelets adhere to exposed collagen Collagen binding results in platelet activation 	3 Platelet adhesion Resting platelets For the second adhere to exposed ubendothelial surface f damaged endothelium.





الـCa بعمل activate group of receptors اسـمهم GP IIb/IIIa بكون موجود على الـsurface تبع الplatelets وبحالة الـresting platelets بكون inactive بس لما يصيرplatelets activation والـCa يزيد بعمله activation

وظيفة هذا ال receptor هي ربط الfibrinogen وبستخدمه كsticking material وطيفة هذا ال

Formation of Plug

• Tissue factors + activated platelets \rightarrow

prothrombin \rightarrow thrombin

Thrombin (IIa): is a serine protease that catalyzes:

fibrinogen \rightarrow fibrin



Fibrinolysis

بتشتغل بالعكس عشان نعمل control للsize of the thrombus

- tPA converts plasminogen to plasmin
 - Plasmin limits the growth of the clot and dissolves the fibrin network



The glycoprotein that facilitates platelets aggregation and is cleaved to form fibrin clot is <u>Fibrinogen</u>

The serine protease that is involved in the formation of the fibrin clot is Thrombin

The enzyme that is responsible for dissolving the fibrin clot is

<u>Plasmin</u>

What happens if:

 You pharmacologically interfere with the increase in platelet intracellular calcium upon tissue injury?

Can you think of components of the platelet activation pathway that can be drug targets?

- COX-1
- GP IIa/IIIb
- ADP receptors

Medication	Adverse Effects	Drug Interactions	Monitoring Parame <u>ters</u>
Oral Agents:			
Aspirin	Angioedema Bleeding Bronchospasm Gl disturbances Reye syndrome SJS	ketorolac—increased bleeding cidofovir—nephrotoxicity probenecid—decreased uricosuric effects	CBC LFT
Cilostazol	Bleeding Gl disturbances Headache Peripheral edema SJS	Food (administer on empty stomach)	CBC
Clopidogrel	Bleeding SJS	Strong CYP2C19 inhibitors reduce antiplatelet effect (e.g., <i>omeprazole</i>)	CBC LFT
Dipyridamole	Bleeding Dizziness Gi discomfort Rash	Salicylates Thrombolytic agents	None for oral administration
Prasugrel	Angioedema Bleeding Headache Hyperlipidemia Hypertension	Anticoagulants Other antiplatelets	СВС
Ticlopidine	Abnormal LFT Bleeding Dizziness Gi disturbances SJS	Antacids—decreases levels Cimetidine—reduces clearance	CBC LFT platelet count
Ticagrelor	Bleeding Dyspnea Headache Raised SCr	Strong CYP3A4 inhibitors (e.g., ketoconazole) Strong CYP3A4 inducers (e.g., rifampin)	CBC LFT
Injectable Agents	:		
Abciximab	For all agents:	For all agents:	For all agents:
Eptifibatide Tirofiban	Hypotension Nausea Vomiting Thrombocytopenia	Increased bleeding: Ginkgo biloba Antiplatelets Salicylates SSBLe and SNBLe	APTT clotting time H/H platelet count thrombin time

Platelet Aggregation inhibitors

Main effects

- Decrease the formation of platelet-rich fibrin clot
 - Interfere with chemical signals that promote platelet aggregation

Can antiplatelets dissolve a formed fibrin clot?

Therapeutic uses:

- 1. Prevention and treatment of occlusive cardiovascular diseases
- 2. Maintenance of vascular grafts and arterial patency
- 3. Treatment of MI (adjunct)

Can you use antiplatelets solely for the immediate management of myocardial infarction?

Aspirin

Mechanism of Action

• Platelet stimulation by ADP, thrombin, exposed collagen leads to:

membrane phospholipase \rightarrow arachidonic acid release \rightarrow prostaglandin synthesis

 Thromboxane A₂ → platelet activation/aggregation/plug formation



الblock بعملblock للCOX بالتالي بمنع ال aspirin

• What does aspirin do?

Irreversibly inhibits COX-1 by acetylation of a

serine residue on its active site

- Rapid
- Prolonged (lasts up to 7-10 days)

